This company has been acquired
Masimo (MASI) Hisse Özeti
Masimo Corporation, dünya çapında çeşitli hasta izleme teknolojilerinin ve otomasyon ve bağlantı çözümlerinin geliştirilmesi, üretimi ve pazarlanmasıyla ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 5/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
MASI Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Masimo Corporation Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$179.95 |
| 52 Haftanın En Yüksek Seviyesi | US$179.99 |
| 52 Haftanın En Düşük Seviyesi | US$125.94 |
| Beta | 1.1 |
| 1 Aylık Değişim | 0.92% |
| 3 Aylık Değişim | 2.55% |
| 1 Yıllık Değişim | 7.09% |
| 3 Yıllık Değişim | 12.45% |
| 5 Yıllık Değişim | -19.88% |
| Halka arzdan bu yana değişim | 761.00% |
Son Haberler & Güncellemeler
MASI: Patent Rulings And Merger Vote Will Shape Future Returns
Analysts have kept Masimo's fair value estimate steady at $180, with only modest tweaks to the discount rate and projected P/E assumptions driving the latest price target update. Analyst Commentary Recent Street research around Masimo points to a mixed but focused debate on valuation, execution, and the impact of corporate actions, especially in relation to broader medtech peers.MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns
Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.Recent updates
MASI: Patent Rulings And Merger Vote Will Shape Future Returns
Analysts have kept Masimo's fair value estimate steady at $180, with only modest tweaks to the discount rate and projected P/E assumptions driving the latest price target update. Analyst Commentary Recent Street research around Masimo points to a mixed but focused debate on valuation, execution, and the impact of corporate actions, especially in relation to broader medtech peers.MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns
Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.MASI: Danaher Cash Offer And Legal And Deal Completion Risks Will Dominate
The analyst fair value estimate for Masimo has been adjusted from $177 to $180, with analysts pointing to the agreed $180 per share cash acquisition by Danaher as the key anchor for updated price targets and ratings. Analyst Commentary Recent research on Masimo has shifted from growth driven valuation debates to a focus on the agreed US$180 per share cash offer from Danaher as the primary reference point for fair value and ratings.MASI: Danaher Cash Offer And Legal Outcomes Will Steer Deal Path
The analyst price target for Masimo has been trimmed by about $1.60 to $177.00, as analysts factor in a slightly higher discount rate and a modestly lower future P/E, while aligning expectations with the $180 per share cash acquisition offer from Danaher. Analyst Commentary Recent research on Masimo has become highly focused on the agreed cash acquisition by Danaher at $180 per share, with most coverage shifting from long term growth narratives to deal related outcomes and near term valuation anchor points.MASI: Danaher Cash Offer And Patent Rulings Will Shape Deal Outcome
Analysts kept Masimo's fair value estimate steady at $178.60 while aligning their price targets around the agreed $180 per share cash acquisition by Danaher, with recent rating changes reflecting the view that any potential upside is now largely tied to the deal closing as planned. Analyst Commentary Recent research on Masimo centers on the agreed US$180 per share cash offer from Danaher, with ratings and targets now clustered around that level.MASI: Danaher Cash Deal And Legal Overhang Will Frame Future Returns
The updated analyst price target for Masimo edges down by $0.15 to $178.60, as analysts anchor their views to Danaher's agreed $180 per share cash acquisition and recent rating moves to Neutral or No Rating. Analyst Commentary Recent research around Masimo has centered on the agreed US$180 per share cash acquisition by Danaher, with most analysts reframing their views around deal completion rather than standalone upside or downside.MASI: Danaher Cash Buyout Will Define Future Returns And Key Risks
Analysts have trimmed their Masimo fair value estimate from $183.13 to $178.75 to align expectations with the agreed $180 per share cash acquisition by Danaher. This shift is reflected in new Hold and Neutral ratings that are centered around the $180 level.Masimo: Danaher Acquisition Saves The Company From Lackluster Performance
Summary Masimo Corporation agreed to be acquired by Danaher for $180/share, valuing MASI at $9.9B. The acquisition offers a strong strategic fit, combining MASI's non-invasive oximetry with DHR's invasive diagnostics for comprehensive acute care solutions. Shareholders benefit from a 34% stock price surge and a potential 2.8% spread to deal close, with minimal market risk. Holding MASI shares until the deal closes offers a relatively safe, low-stress return, though opportunity cost and regulatory risk remain. Read the full article on Seeking AlphaMASI: Renewed Philips Partnership Will Drive Outperformance Despite Market Challenges
Analysts have adjusted their price target for Masimo downward from approximately $188 to $183. This change is attributed to shifts in revenue growth estimates and a strengthening profit margin following recent partnership developments and ongoing market challenges.Is Masimo Corporation (NASDAQ:MASI) Potentially Undervalued?
Masimo Corporation ( NASDAQ:MASI ), might not be a large cap stock, but it received a lot of attention from a...Calculating The Fair Value Of Masimo Corporation (NASDAQ:MASI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Masimo fair value estimate is US$136 Masimo's US$154 share...Masimo: Priced Dearly Given Uncertainty
Summary Masimo Corporation, a mid-cap healthcare firm, has a new CEO and is navigating considerable uncertainty. Some aspects of the company's divestiture of its consumer business are still unclear. Despite this, the stock is generally well liked within the analyst firm community, following solid Q4 results. An analysis around Masimo Corporation follows in the paragraphs below. Read the full article on Seeking AlphaMasimo: A Stellar Performance After The Dust Has Settled
Summary Masimo's proxy fight and Sound United acquisition distracted from the core business, but resolution and focus on healthcare are driving value and momentum. Shares surged over 50% since July due to strong Q2 results and improved earnings guidance, despite ongoing challenges and leadership changes. Current valuations are demanding, suggesting an opportune time for profit taking, while I maintain a position for long-term growth potential. Divesting Sound United could reduce debt, enhancing focus on the core med-tech business with promising double-digit organic growth. Read the full article on Seeking AlphaHissedar Getirileri
| MASI | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 0.7% | 2.2% | -2.7% |
| 1Y | 7.1% | -20.9% | 18.6% |
Getiri vs. Endüstri: MASI geçen yıl % -20.9 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: MASI geçen yıl % 18.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| MASI volatility | |
|---|---|
| MASI Average Weekly Movement | 0.6% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: MASI son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: MASI 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 6% dan 1% a düştü.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1989 | 2,200 | Katie Szyman | www.masimo.com |
Masimo Corporation, dünya çapında çeşitli hasta izleme teknolojilerinin ve otomasyon ve bağlantı çözümlerinin geliştirilmesi, üretimi ve pazarlanmasıyla ilgilenmektedir. Geleneksel nabız oksimetresinin birincil sınırlamalarını ele almak için hareket ve düşük perfüzyon nabız oksimetresi izleme ile Masimo Signal Extraction Technology (SET) nabız oksimetresi; oksijen, karboksihemoglobin ve methemoglobinin noninvaziv izlenmesini sağlayan rainbow SET Pulse CO-Oximetry ürünleri de dahil olmak üzere Masimo Rainbow SET platformu sunmaktadır. Ayrıca beyin fonksiyonu ve hemodinamik izleme çözümleri; hasta pozisyonu ve aktivite takibi ve nöromodülasyon teknolojisi çözümleri; ve Patient SafetyNet, Iris, iSirona, Replica ve UniView dahil hastane otomasyon çözümlerini içeren Masimo Hastane Otomasyon platformu; ve beyin fonksiyonu izleme, hemodinamik izleme, bölgesel oksimetre, akustik solunum hızı izleme, kapnografi ve gaz izleme ve tele-sağlık çözümleri sunmaktadır.
Masimo Corporation Temel Bilgiler Özeti
| MASI temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$9.42b |
| Kazançlar(TTM) | US$216.80m |
| Gelir(TTM) | US$1.56b |
MASI aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| MASI gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.56b |
| Gelir Maliyeti | US$598.00m |
| Brüt Kâr | US$960.50m |
| Diğer Giderler | US$743.70m |
| Kazançlar | US$216.80m |
Son Raporlanan Kazançlar
Apr 04, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 4.14 |
| Brüt Marj | 61.63% |
| Net Kâr Marjı | 13.91% |
| Borç/Özkaynak Oranı | 57.3% |
MASI uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/09 17:15 |
| Gün Sonu Hisse Fiyatı | 2026/06/09 00:00 |
| Kazançlar | 2026/04/04 |
| Yıllık Kazançlar | 2026/01/03 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Masimo Corporation 20 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Polark | Baird |
| Charley Jones | Barrington Research Associates, Inc. |
| Ravi Misra | Berenberg |